# Affinia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affinia-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.affiniatx.com/
- Total disclosed funding: $163M
- Latest round: Series C (Sep 16, 2025)
- Investors on record: 18

## About

Founded in 2019 by Aaron Tward, Luk Vandenberghe, and Rob Aboud and based in Massachusetts, US, Affinia Therapeutics, Inc. is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies. Rick Modi serves as the CEO of the company as of 2025. In September 2025, Affinia Therapeutics, Inc. raised USD 13.27 million in series C funding led by new investor New Enterprise Associates, with participation from another new investor, Eli Lilly & Company. Returning investors Alexandria Venture Investments, Atlas Venture, Avidity Partners Management, F-Prime Venture, GV, Mass General Brigham Ventures, and Perceptive Advisors also participated in the round. Other unspecified investors also participated in the round
 
The company’s platform enables scientists to methodically engineer the next generation of AAV vectors and gene therapies. The therapies can be used to overcome both tissue selectivity and immunogenicity and also to manufacture yields, and payload capacity.

The company’s research relies on the use of synthetic and systems biology, combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases. The platform is used by medical professionals to achieve the rational design of novel vectors and gene therapies. Affinia Therapeutics, Inc.  generates revenue by developing and licensing gene therapy programs using proprietary cardiotropic AAV capsid technology for rare genetic cardiac and neuromuscular diseases.
 
In September 2025, Affinia Therapeutics, Inc. raised USD 13.27 million in series C funding led by new investor New Enterprise Associates, with participation from another new investor, Eli Lilly & Company. Returning investors Alexandria Venture Investments, Atlas Venture, Avidity Partners Management, F-Prime Venture, GV, Mass General Brigham Ventures, and Perceptive Advisors also participated in the round. Other unspecified investors also participated in the round. The company will use the funding to support clinical trials and expand development of its gene therapy programs.

## Funding rounds

- Series C, Sep 16, 2025, $13M — Atlas Venture, New Enterprise Associates, Alexandria Venture Investments, F-Prime Capital, GV, Mass General Brigham Ventures, Eli Lilly & Company, Perceptive Advisors, Avidity Partners Management
- Series B, Apr 20, 2021, $110M — Atlas Venture, New Enterprise Associates, F-Prime Capital, GV, Lonza Group Ltd., Mass General Brigham Ventures, Casdin Capital, RA Capital Management, EcoR1 Capital, Farallon Capital Management, Perceptive Advisors, Woodline Partners, Octagon Capital Advisors, Avidity Partners, TCG Crossover Management
- Series A, Mar 31, 2020, $40M — Atlas Venture, New Enterprise Associates, Alexandria Venture Investments, F-Prime Capital, Lonza Group Ltd., Mass General Brigham Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C
- Lonza Group Ltd. — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Woodline Partners — Series B
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B
- Avidity Partners — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Eli Lilly & Company — Series C
- Avidity Partners Management — Series C